Impression receives research & development grant
Impression Healthcare (ASX:IHL), an Australian ‘dental-impression’ company, has received $263,279 from the Australian Taxation Office under the Research and Development Tax Incentive Scheme for the 2017 financial year.
The funds will be deployed to further Impression’s direct business strategy of offering consumers a high-quality and more-affordable night guard for the treatment of bruxism (teeth grinding and clenching) without the need to be prescribed or fitted by a dentist.
Impression has developed several unique products for the DIY-dental market niche and intends to scale-up its activities over time via product development, wider distribution reach and higher unit sales.
The Knight Guard is an effective means of mitigating bruxism while The Sleep Guardian is a anti-snoring device. These products are attempting to satiate a significant and growing demand for affordable and customised dental devices, without high expenses or having to visit a dentist.
Earlier this month, Impression sold its 1,000th unit of the Knight Guard.
Both the Sleep Guardian and the Knight Guard use an impression kit manufactured by qualified dental technicians at Impression’s laboratory in Victoria, Australia. All customers are able to access the full spectrum of functionality Impression has access to.
According to Impression, both the Knight Guard and Sleep Guardian are “relatively higher-value products that are markedly increasing revenue flow and reduce seasonality of sales”. November’s sales figures rising 83% month-to-date and 89% on a quarterly basis and Impression reports that there have been 7,593 unique visits to its website and 140,000 views of its product-specific Facebook page.
Despite the growth this remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.
Impression will utilise the funds raised from recent capital raisings to expand its digital marketing, print and TV advertising campaigns in order to educate customers about Impression’s products as well as to scale up its company operations.
Impression is also evaluating the possibility of working with complementary service providers (such as sleep therapists) as affiliates, who would be in a position to promote the Sleep Guardian/Knight Guard.
Impression could not provide further information regarding its intended affiliate programme but did confirm it “will update the market as and when any formal arrangements may be executed.”
Impression’s current CEO Matt Weston said, “New product offerings recently introduced are helping sales momentum and we continue to evaluate initiatives in the pipeline that will increase brand value and increase sales across our suite of products.”
“Early sales of the Sleep Guardian have been procured on minimal marketing spend to date and we look forward to increasing sales of the Sleep Guardian with a co-ordinated marketing campaign to commence in early 2018.”
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.